



# THIRD-QUARTER 2024 RESULTS

## TOTAL COMPANY

# \$10.6B +8.2%<sup>1</sup>

SALES  
WORLDWIDE

Organic\* sales growth for  
underlying base business\*\*

# \$1.21<sup>2</sup>

ADJUSTED DILUTED EPS

## BUSINESS HIGHLIGHTS

### CGM FOR HEALTH AND WELLNESS NOW AVAILABLE IN THE U.S.

- ▶ Announced the U.S. launch of Lingo™\*\*\*, the company's first continuous glucose monitoring (CGM) system available without a prescription and designed for people interested in improving their overall health and wellness.



## KEY BUSINESS UNITS<sup>3</sup>



# 13.3%

MEDICAL DEVICES



# 3.3%

DIAGNOSTICS



# 7.0%

ESTABLISHED  
PHARMACEUTICALS



# 3.4%

NUTRITION

### EXPANDING CONNECTIVITY FOR FREESTYLE LIBRE<sup>®†</sup> TECHNOLOGY

- ▶ Announced a unique global partnership with Medtronic to collaborate on connecting Abbott's world-leading CGM system with Medtronic insulin delivery devices.



### RAISED MIDPOINT OF FULL-YEAR EPS GUIDANCE RANGE

# \$4.64 to \$4.70<sup>4</sup>

ADJUSTED DILUTED EPS

### MAINTAINS FULL-YEAR ORGANIC SALES GROWTH GUIDANCE RANGE

# 9.5% to 10.0%<sup>5</sup>

Excluding COVID-19 testing-related sales

### HELPING INCREASE THE U.S. BLOOD SUPPLY

- ▶ Announced a partnership with the Big Ten Conference to conduct a nationwide blood donation competition.



<sup>1</sup>Organic sales growth excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Oct. 16, 2024, available at [www.abbottinvestor.com](http://www.abbottinvestor.com).

<sup>2</sup>Excludes the impact of COVID-19 testing sales.

<sup>3</sup>The Lingo Glucose System is intended for users 18 years and older not on insulin. It is not intended for diagnosis of diseases, including diabetes. The Lingo program does not guarantee that everyone will achieve the same results as individual responses may vary. Consult your healthcare professional before making changes to your diet or exercise regimen or if you have an eating disorder or a history of eating disorders.

<sup>4</sup>Find important safety information about the FreeStyle Libre portfolio: [www.freestylelibre.us/safety-information](http://www.freestylelibre.us/safety-information).

<sup>5</sup>1. On a GAAP basis, third-quarter 2024 Abbott sales increased 4.9%. 2. Third-quarter 2024 GAAP diluted EPS was \$0.94. 3. On a GAAP basis, third-quarter 2024 Medical Devices sales increased 11.7%, Established Pharmaceuticals sales increased 2.7%, Nutrition sales decreased 0.3% and Diagnostics sales decreased 1.5%. 4. Abbott projects full-year 2024 diluted earnings per share under GAAP of \$3.34 to \$3.40. Abbott forecasts specified items for the full-year 2024 of \$1.30 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be \$4.64 to \$4.70 for the full-year 2024. 5. Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for COVID-19 tests.

#### FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.